Cyclacel Pharmaceuticals Story Overview

CYCC -- USA Stock  

USD 1.39  0.01  0.72%

Macroaxis does not monitor all media channels or aggregates social signals for Cyclacel Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Cyclacel Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Cyclacel Pharmaceuticals. Check also Cyclacel Pharmaceuticals Hype Analysis, Cyclacel Pharmaceuticals Correlation and Cyclacel Pharmaceuticals Performance.
The sentiment expressed by investors TimkenSteel Corporation , Cyclacel ...
Taking a close look at the activity of the stock of TimkenSteel Corporation , during the trading sessions, it is clear to see that the prices of their shares moved to 12.83.

Read More...   

Story Momentum

This media report from financialqz.com distributed on December 7, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 9.29% . The overall trading delta when the story was published against the current closing price is 24.59% .

Similar stores for Cyclacel Pharmaceuticals

few days ago at http://nysewired.com 
Have a look at updown Move Cyclacel Pharmaceuticals
wired  News
NYSE WIRED Full coverage
over three weeks ago at http://advertisingmarket24.com 
Cyclin Dependent Kinase 9 Market Report Updated on 2018 Premium Insights on Industry Growth rate and Trend ...
news
advertisingmarket24.comFull coverage
over a month ago at http://thewellesleysnews.com 
Equity Research Analysts Stock Ratings Cyclacel Pharmaceuticals, Inc. , Trans World Entertainment ...
news
Analyst JournalFull coverage
over a month ago at http://www.benzinga.com 
Benzingas Top Upgrades, Downgrades For September 5, 2018
benzinga news
BenzingaFull coverage
over a month ago at www.macroaxis.com 
Cyclacel Pharmaceuticals exotic insider transaction detected
Macroaxis News
Filed transaction by Cyclacel Pharmaceuticals executive. Unconventional Insider trading
over a month ago at http://pressoracle.com 
Analysts Expect Cyclacel Pharmaceuticals Inc Will Post Earnings of -0.12 Per Share
news
PressOracleFull coverage
over a month ago at http://depositormoney.com 
Global Cyclin Dependent Kinase 9 Sales Market Insights by 2018-2025 Industry Overview, Opportunities, In-Depth...
news
Depositor MoneyFull coverage
over two months ago at http://cardinalweekly.com 
Leuthold Group Has Upped Fiserv Holding by 3.14 Million Share Price Declined Tieton Capital Management ...
news
The Cardinal Weekly Full coverage
over two months ago at http://seekingalpha.com 
Cyclacel Pharmaceuticals, Inc. CEO Spiro Rombotis on Q2 2018 Results - Earnings Call Transcript
seekingalpha News
Seeking AlphaCyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results Markets InsiderFull coverage
over two months ago at http://endigest.com 
Cyclacel Pharmaceuticals, Inc. At 1.65 Forms Bottom INTRUM JUSTITIA AB AMERICAN DEPOSITARY R ...
news
EN DigestFull coverage
over three months ago at http://hillaryhq.com 
First Pacific Advisors Has Upped Its Holding in United Parcel Service Cl B by 800800 as Shares Rose ...
news
Hillary HQ Amazon to Take On UPS, FedEx With New Delivery Vans Yahoo FinanceFull coverage
over three months ago at http://www.analystratings.com 
Analysts Top Healthcare Picks SRPT, ACAD
news
Analyst RatingsFull coverage
over six months ago at http://ledgergazette.com 
ValuEngine Upgrades Cyclacel Pharmaceuticals to Sell
news
The Ledger GazetteFull coverage

Beta

Beta Comparative Analysis

  Beta 
      Cyclacel Pharmaceuticals Comparables 
Cyclacel Pharmaceuticals is currently under evaluation in beta category among related companies. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of financial instrument to the financial market in which this instrument is traded. For example if Beta of equity is 2, it will be expected to significantly outperform market when market is going up and significantly underperform when market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns during over time.

Peers

Cyclacel Pharmaceuticals Related Equities

DOVA  9.06 %   
0%
100.0%
DMPI  7.76 %   
0%
85.0%
EARS  7.25 %   
0%
79.0%
DVAX  5.97 %   
0%
65.0%
ECYT  4.66 %   
0%
51.0%
DRNA  1.75 %   
0%
19.0%
NK  1.45 %   
0%
16.0%
CO  3.46 %   
38.0%
0%
Check also Cyclacel Pharmaceuticals Hype Analysis, Cyclacel Pharmaceuticals Correlation and Cyclacel Pharmaceuticals Performance. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Search macroaxis.com